Effect of renal impairment on the pharmacokinetics of antimony in hamsters

Annals of Tropical Medicine and Parasitology

Volumn 98, Issue 8, 2004, Pages 793-800

  Zaghloul, I Y ^a   Al Jasser, M ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; CREATININE; STIBOGLUCONATE SODIUM; UREA;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; HAMSTER; KIDNEY FAILURE; KIDNEY FUNCTION; LEISHMANIASIS; NEPHROTOXICITY; NONHUMAN; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; BIOLOGICAL AVAILABILITY; CREATININE; CRICETINAE; INJECTIONS, INTRAMUSCULAR; KIDNEY; KIDNEY FAILURE, ACUTE; MESOCRICETUS; METABOLIC CLEARANCE RATE;

ANIMALIA; CRICETINAE; PROTOZOA;

EID: 10944264264     PISSN: 00034983     EISSN: None     Source Type: Journal    
DOI: 10.1179/000349804X3171     Document Type: Article

References (23)

1. Al-Jaser, M. H., El-Yazigi, A. & Croft, S. L. (1995). Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharmaceutical Research, 12, 113-116.
2. Alrajhi, A. A., Inbahim, E. F., de Vol, E., Khairat, M., Paris, R. & Maguire, J. (2002). Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. New England Journal of Medicine, 346, 891-895.
3. Antezana, G., Zeballo, R., Mendoza, C., Lyevre, P., Valda, L., Cardenas, F., Noriega, I. Ugarte, H. & Dedet, J. P. (1992). Electrogardiographic alterations during treatment of mucoucutaneous leishmaniasis with meglumine antimonite and allpurinol. Transactions of the Royal Society of Tropical Medicine and Hygiene, 86, 31-33.
4. Appenroth, D., Lupp, A., Kriegsmann, J., Sawall, S., Splinther, J. Sommer, M., Stien, G. & Fleck, C. (2001). Temporary warm ischemia, 5/6 nephrectomy and single uranyl nitrate administration - comparison of three models intended to cause renal fibrosis in rats. Experimental and Toxicologic Pathology, 53, 316-324.
5. Berman, J. D., Gallalee, J. F. & Gallalee, J. V. (1988). Pharmacokinetics of pentavalent antimony (Pentostam) in hamsters. American Journal of Tropical Medicine and Hygiene, 39, 41-45.
6. Brophy, D. F. (2001). Acute renal failure. In Applied Therapeutics, the Clinical Use of Drugs, 7th Edn, eds Koda-Kimble, M. A. & Young, L. Y. pp. 1-2 of Chapter 29. New York: Lippincott, Williams & Wilkins.
7. Chulay, J. D., Fleckenstien, L. & Smith, D. H. (1988). Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimonite. Transactions of the Royal Society of Tropical Medicine and Hygiene, 82, 69-72.
8. Delagado, J., Macias, J., Pineda, J. A., Corzo, J. E., Gonzalez-Moreno, M. P., de la Rosa, R., Sanchez-Quijano, A., Leal, M. & Lissen, E. (1999). High frequency of serious side effects from meglumine antimonite given without an upper limits dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. American Journal of Tropical Medicine and Hygiene, 61, 766-769.
9. Gibaldi, M. & Ferner, D. (1982). Pharmacokinetics, 2nd Edn. New York: Marcel Dekker.
10. Hantson, P., Luyasu, S., Haufroid, V. B. & Lambert, M. (2000). Antimony excretion in a patient with renal impairment during meglumine antimoniate therapy. Pharmacotherapy, 20, 1141-1143.
11. Hepburn, N. C. (2001). Management of cutaneous leishmaniasis. Current Opinion in Infectious Diseases, 14, 151-154.
12. Hudson, J. Q. & Johnson, C. A. (2001). Chronic renal failure. In Applied Therapeutics, the Clinical Use of Drugs, 7th Edn, eds Koda-Kimble, M. A. & Young, L. Y. p. 2 of Chapter 30. New York: Lippincott, Williams & Wilkins.
13. Lazanas, M. C., T'sekes, G. A., Papandreous, S., Harhalakis, N., Scandali, A., Niiforakis, E. & Saroglou, G. (1993). Liposomal amphotericin B for the treatment of AIDS patients unresponsive to antimonial compounds. AIDS, 7, 1018-1019.
14. Rai, U. S., Kumar, H. & Kumar, U. (1994). Renal dysfunction in patients of kala-azar treated with sodium antimony gluconate. Journal of the Association of Physicians of India, 42, 383.
15. Rees, P. H., Keating, M. I., Kager, P. A. & Hockameyer, W. T. (1980). Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet, ii, 226-229.
16. Sampaio, R. N., de Paula, C. D., Sampaio, J. H., Furtado, R. de S., Leal, P. P. & Rosa, T. T. Rodrigues, M. E. & Veiga, J. P. (1997). The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg SbV/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical, 30, 457-463.
17. Soto, J., Buffet, P., Grogl, M. & Herman, J. (1994). Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. American Journal of Tropical Medicine and Hygiene, 50, 107-111.
18. Sundar, S., Argwal, G., Rai, M., Makharia, M. K. & Murray, H. W. (2001). Treatment of Indian visceral leishmaniasis with single or daily infusion of low dose liposomal amphotericin B: randomized trial. British Medical Journal, 323, 419-422.
19. Sundar, S., Jha, T. K., Sindermann, H., Junge, K., Bachmann, P. & Berman, J. (2003). Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatric Infectious Disease Journal, 22, 434-438.
20. Veiga, J. P., Wolff, E. R., Sampaio, R. N. & Marsden, P. D. (1983). Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials. Lancet, ii, 569.
21. Veiga, J. P., Khanam, R., Rosa, T. T., Junqueira Jr, L. F., Brant, P. C., Friedman, H. & Marsden P. D. (1990). Pentavalent antimonial nephrotoxicity in the rat. Revista do Instituto de Medicina Tropical de São Paulo, 32, 304-309.
22. World Health Organization (1984). The Leishmaniases. Technical Report Series No 71. Geneva: WHO.
23. Zijlstra, E. E., Siddig Ali, M., El-Hassan, A. M., Hofland, H. W., El-Toum, I., Satti, M. & Ghalib, H. W. (1993). Treatment of kala-azar in the Sudan with sodium stibogluconate, a randomized trial of three dosage regimens. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87, 307-309.